Drugs /

rimiducid

Back to Drugs List

Overview

Generic Name(s):
rimiducid

Clinical Trials

View Clinical Trials for rimiducid

Rimiducid has been investigated in 11 clinical trials, of which 10 are open and 1 is closed. Of the trials investigating rimiducid, 5 are phase 1 (4 open) and 6 are phase 1/phase 2 (6 open).

Complex karyotype, Monosomy 7, and Very Complex karyotype are the most frequent biomarker inclusion criteria for rimiducid clinical trials.

Acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndromes are the most common diseases being investigated in rimiducid clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rimiducid
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rimiducid
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rimiducid and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ap1903
Drug Target(s) [2]:
FKBP1A
NCIT ID [1]:
C82412

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.